Comparing Two Treatments for Malaria in Uganda
Author Information
Author(s): Kamya Moses R, Yeka Adoke, Bukirwa Hasifa, Lugemwa Myers, Rwakimari John B, Staedke Sarah G, Talisuna Ambrose O, Greenhouse Bryan, Nosten François, Rosenthal Philip J, Wabwire-Mangen Fred, Dorsey Grant
Primary Institution: Department of Medicine, Makerere University, Kampala, Uganda
Hypothesis
Is dihydroartemisinin-piperaquine (DP) more effective than artemether-lumefantrine (AL) for treating uncomplicated falciparum malaria in children?
Conclusion
Dihydroartemisinin-piperaquine (DP) is more effective than artemether-lumefantrine (AL) in reducing the risk of recurrent malaria in children.
Supporting Evidence
- Patients treated with DP had a significantly lower risk of recurrent parasitemia compared to those treated with AL.
- The risk of recurrent parasitemia due to possible recrudescence was also lower in the DP group.
- Both treatments were well tolerated with few serious adverse events.
Takeaway
This study found that one medicine worked better than another for treating malaria in kids, helping them stay healthy longer.
Methodology
A randomized single-blinded clinical trial comparing the efficacy and safety of AL and DP in children with uncomplicated falciparum malaria.
Potential Biases
Potential incomplete blinding of participants as the study drugs had different appearances.
Limitations
Difficulty in distinguishing between recrudescence and new infections due to high complexity of infections.
Participant Demographics
Children aged 6 months to 10 years with uncomplicated falciparum malaria.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 11%–26%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website